Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.

Published

Journal Article (Review)

Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance therapy. Maintenance therapy has been shown to enhance progression-free survival. Recent surgical trials have evaluated the role of neoadjuvant chemotherapy versus primary debulking at the time of diagnosis in advanced stage ovarian cancer. The role of lymph node dissection and secondary cytoreductive surgeries have also been evaluated. This article reviews contemporary trials of maintenance therapy and novel drug development.

Full Text

Duke Authors

Cited Authors

  • Previs, RA; Secord, AA

Published Date

  • March 2019

Published In

Volume / Issue

  • 46 / 1

Start / End Page

  • 67 - 88

PubMed ID

  • 30683267

Pubmed Central ID

  • 30683267

Electronic International Standard Serial Number (EISSN)

  • 1558-0474

Digital Object Identifier (DOI)

  • 10.1016/j.ogc.2018.09.005

Language

  • eng

Conference Location

  • United States